ClinicalTrials.gg
CompletedNCT03368807Updated Aug 2, 2019Results posted

Assessment of Mealtime Bolus Insulin Behavior

An observational study in Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-02.

Sponsored by Eli Lilly and Company · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
79
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.

Started
2017
with 6 others
Observational
3 of 75
none open now
Registered
42nd of 75
by date

Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is one of 7 that started in 2017, is one of 3 observational ones, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.

03

Conditions studied

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Type 1 and Type 2 Diabetics

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a Type 1 Diabetes Mellitus (T1D) or a Type 2 Diabetes Mellitus (T2D) diagnosis
  • Must be taking a mealtime bolus dose insulin, greater than or equal to (≥) 3 doses
  • Each individual bolus insulin dose must be less than (\<) 40 units
  • Must be taking a stable insulin dose regimen for the last 3 months
  • Must be taking a bolus insulin analog (for example insulin lispro [U-100]/[U-200], insulin aspart, or insulin glulisine). In addition, must be able to switch to insulin lispro U-100 for the duration of the trial
  • Must have a (HbA1c) ≥8.0% in the last 6 months
  • Participants with T1D must be ≥21 to less than or equal to (≤) 65 years of age. Participants with T2D must be ≥35 to ≤65 years of age
  • Women of must meet the following: (Note: females of childbearing potential are defined as those who have experienced menarche and who are NOT permanently sterile or . Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause)

    • Must agree to use 1 highly effective method of , or a combination of 2 effective methods of contraception for the entirety of the study
    • Must test negative for pregnancy as indicated by a negative serum or urine pregnancy test
  • Participants with prior CGM/flash glucose monitoring experience must have stopped CGM/flash glucose monitoring ≥3 months prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Have known tape/adhesive allergies with CGM sensors
  • Medical conditions, visual, physical, psychiatric, or cognitive impairment(s) that may preclude the ability to participate in the trial
  • Have history of liver disease, acute or chronic hepatitis, or or aspartate aminotransferase levels ≥3 times the upper limit of the reference range within the last 6 months
  • Have history of chronic kidney disease stage 4 and higher within the last 6 months, or history of renal transplantation
  • Have active
  • Are pregnant or planning to become pregnant
  • Are on or are intending to begin a weight loss program
  • Participants with T1D who have taken off-label antihyperglycemic agents within last 3 months
  • Have received insulin by continuous subcutaneous insulin infusion in the last 3 months
  • Participants taking opioid medications for medically invalid reasons or at doses considered excessive
  • Participants on routine use of acetaminophen
  • Currently undergoing systemic treatment with:

    • medication
    • Chronic (lasting longer than 2 weeks) systemic therapy (excluding topical and inhaled preparations) or have received such therapy within the prior 2 weeks
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated, within the last 30 days, in a clinical study involving an investigational product
  • Are unwilling or unable to comply with the use of a data collection device to directly record data
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
79 participants (actual)
Patient registry
No

Groups and cohorts

  • Blinded CGM (Continuous Glucose Monitoring)

    Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.

    Device: Continuous Glucose Monitoring · Drug: Insulin Lispro

  • Unblinded CGM

    Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.

    Device: Continuous Glucose Monitoring · Drug: Insulin Lispro

Interventions

  • DeviceContinuous Glucose Monitoring

    Commercially available

  • As prescribed.

06

What researchers measure

Primary outcomes

  1. Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM

    The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively.

    Time frame: Week 1 up to 6 weeks

Secondary outcomes

  1. Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM

    The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using unblinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively

    Time frame: Week 6 up to 12 weeks

  2. Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM

    Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on blinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.

    Time frame: Baseline up to 6 weeks

  3. Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM

    Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on unblinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.

    Time frame: Week 6 up to 12 weeks

  4. Percentage of Missed Bolus Doses Per Month With Blinded CGM

    Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.

    Time frame: Baseline up to 6 weeks

  5. Percentage of Missed Bolus Doses Per Month With Unblinded CGM

    Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM measurements and the pen.

    Time frame: Week 6 up to 12 weeks

  6. Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM

    The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.

    Time frame: Baseline up to 6 weeks

  7. Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM

    The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM data.

    Time frame: Week 6 up to 12 weeks

  8. Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM

    The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.

    Time frame: Baseline up to 6 weeks

  9. Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM

    The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.

    Time frame: Week 6 up to 12 weeks

07

Results

Posted Aug 2, 2019

Participant flow

Period 1 (Blinded CGM)
Participant flow — Period 1 (Blinded CGM)
MilestoneStudy Period 1/Study Period 2
Started79
Received at least 1 dose of study drug78
Completed73
Not completed6
Withdrew: Withdrawal by subject3
Withdrew: Protocol violation1
Withdrew: Sponsor decision1
Withdrew: Lost to follow-up1
Period 2 (Unblinded CGM)
Participant flow — Period 2 (Unblinded CGM)
MilestoneStudy Period 1/Study Period 2
Started73
Completed73
Not completed0

Outcome measures

PrimaryAverage Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM

The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using blinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively.

Time frame:
Week 1 up to 6 weeks
Reported as:
Mean · Days per month
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM
Days per monthBlinded CGM
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Blinded CGM19.3 ± 6.2
SecondaryAverage Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM

The average number of days per month with a missed bolus insulin dose was calculated in participants with Type 1 Diabetes or Type 2 Diabetes using unblinded CGM measurements and the pen. The time of insulin dosing and glucose excursions were assessed using the display times recorded by the pen and CGM devices, respectively

Time frame:
Week 6 up to 12 weeks
Reported as:
Mean · Days per month
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM
Days per monthUnblinded CGM
Average Number of Days Per Month With a Missed Bolus Insulin Dose With Unblinded CGM17.9 ± 5.7
SecondaryPercentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM

Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on blinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.

Time frame:
Baseline up to 6 weeks
Reported as:
Mean · Percentage of time
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM
Percentage of timeBlinded CGM
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Blinded CGM42.7 ± 18.8
SecondaryPercentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM

Percentage of time-in-range (glucose \>70 and ≤180 milligrams per deciliter) was calculated in participants with Type 1 Diabetes or Type 2 Diabetes based on unblinded CGM data collected in the study period. The time component of the time-in-range statistic was calculated using the display time recorded by the CGM device.

Time frame:
Week 6 up to 12 weeks
Reported as:
Mean · Percentage of time
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM
Percentage of timeUnblinded CGM
Percentage of Time-in-Range (Glucose >70 and ≤180 Milligrams Per Deciliter) With Unblinded CGM49.6 ± 20.0
SecondaryPercentage of Missed Bolus Doses Per Month With Blinded CGM

Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.

Time frame:
Baseline up to 6 weeks
Reported as:
Mean · Percentage of missed bolus dose
Percentage of Missed Bolus Doses Per Month With Blinded CGM
Percentage of missed bolus doseBlinded CGM
Percentage of Missed Bolus Doses Per Month With Blinded CGM25.3 ± 12.3
SecondaryPercentage of Missed Bolus Doses Per Month With Unblinded CGM

Percentage of missed bolus doses per month was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM measurements and the pen.

Time frame:
Week 6 up to 12 weeks
Reported as:
Mean · Percentage of missed bolus dose
Percentage of Missed Bolus Doses Per Month With Unblinded CGM
Percentage of missed bolus doseUnblinded CGM
Percentage of Missed Bolus Doses Per Month With Unblinded CGM23.3 ± 10.2
SecondaryAverage Number of Missed Bolus Insulin Doses Per Day With Blinded CGM

The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using blinded CGM measurements and the pen.

Time frame:
Baseline up to 6 weeks
Reported as:
Mean · Dose per day
Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM
Dose per dayBlinded CGM
Average Number of Missed Bolus Insulin Doses Per Day With Blinded CGM0.9 ± 0.4
SecondaryAverage Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM

The average number of missed bolus doses per day was estimated in participants with Type 1 diabetes or Type 2 diabetes using unblinded CGM data.

Time frame:
Week 6 up to 12 weeks
Reported as:
Mean · Dose per day
Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM
Dose per dayUnblinded CGM
Average Number of Missed Bolus Insulin Doses Per Day With Unblinded CGM0.9 ± 0.4
SecondaryAverage Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM

The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.

Time frame:
Baseline up to 6 weeks
Reported as:
Mean · Dose per month
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM
Dose per monthBlinded CGM
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Blinded CGM68.3 ± 24.1
SecondaryAverage Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM

The number of Missed and Suboptimal Doses (MSBDs) per month was calculated in participants with Type 1 Diabetes or Type 2 Diabetes as the sum of the identified missed bolus doses and suboptimal bolus doses for each participant for each period.

Time frame:
Week 6 up to 12 weeks
Reported as:
Mean · Dose per month
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM
Dose per monthUnblinded CGM
Average Number of Missed and Suboptimal Bolus Dose (MSBD) Events Per Month With Unblinded CGM61.9 ± 22.2

Adverse events

Collected over Up To 12 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinded CGM0/78 (0%)3/78 (3.8%)22/78 (28.2%)
Unblinded CGM0/73 (0%)2/73 (2.7%)9/73 (12.3%)
Most frequent serious events
Most frequent serious events
EventBlinded CGMUnblinded CGM
Localised infectionInfections and infestations0/782/73
Chest painGeneral disorders1/780/73
HypoglycaemiaMetabolism and nutrition disorders1/780/73
Medical device removalSurgical and medical procedures1/780/73
Most frequent other events
Showing 10 of 32
Most frequent other events
EventBlinded CGMUnblinded CGM
InfluenzaInfections and infestations3/781/73
Upper respiratory tract infectionInfections and infestations3/780/73
BradycardiaCardiac disorders0/781/73
Chest painGeneral disorders0/781/73
NasopharyngitisInfections and infestations1/781/73
OnychomycosisInfections and infestations0/781/73
Humerus fractureInjury, poisoning and procedural complications0/781/73
HypoglycaemiaMetabolism and nutrition disorders0/781/73
Device damageProduct Issues0/781/73
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/781/73

Baseline characteristics

All enrolled participants who received study drug.

Age, Continuous
Age, Continuous(Years)Overall Study
Mean48.01 ± 11.71
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female36
Male43
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino13
Not Hispanic or Latino66
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White73
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
United States79
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Overall Study
Mean30.9 ± 6.1
08

Study locations

6 sites
  • AMCR Institute, Inc.
    Escondido, California 92025, United States
  • Science 37 Inc
    Los Angeles, California 90045, United States
  • Coastal Metabolic Research Ctr
    Ventura, California 93003, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Iowa Diabetes & Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jun 2018, 6 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 6 months is below that.

Counting every sponsor, half of 299 studies reached it within 30 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 11, 2017
StartActual
Dec 11, 2017
Primary completionActual
Jun 12, 2018
CompletionActual
Jul 23, 2018
Results first posted
Aug 2, 2019
Last update
Aug 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03368807
Responsible party
Sponsor
First posted
Dec 11, 2017
Start date
Dec 11, 2017
Primary completion
Jun 12, 2018
Completion
Jul 23, 2018
Results posted
Aug 2, 2019
Last update
Aug 2, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion